Charts

Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2024. To part

Investors in Ardelyx Inc (ARDX) saw new options become available this week, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain for the new May 31st contracts and identified one put and one call contract of particular interest.

Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported ...

Analysts' ratings for Ardelyx (NASDAQ:ARDX) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors looking to strike it rich should consider adding these three transformative stocks to their portfolio. The post The Millionaire’s Shortcut: 3 Stocks to Transform Your Portfolio This Month appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Symbols mentioned in this story: DWAS, MOD, ACIC, ARDX Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on March 25, 2024, the compensation committee of the company’s board of directors granted a non-qualified stock option award to purchase 205,000 shares of its common stock and a restricted stock unit award for 160,000 shares in

Investors in Ardelyx Inc (ARDX) saw new options become available today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain for the new May 10th contracts and identified one put and one call contract of particular interest.

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to

Key Insights Given the large stake in the stock by institutions, Ardelyx's stock price might be vulnerable to their...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Explore why these stocks may explode and could be game-changers in biotechnology, hotels, resorts, cruise lines, and application software. The post The Clock is Ticking: 3 Stocks Set to Explode in the Next Quarter appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

Investors in Ardelyx Inc (ARDX) saw new options begin trading today, for the April 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain for the new April 26th contracts and identified one put and one call contract of particular interest.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips From biotechnology to digital tech endeavors, these stocks offer huge promise for the future, making them stocks to buy now. The post The Millionaire’s Watchlist: 3 Stocks Set for a Meteoric Rise appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Susan Rodriguez, chief commercial officer of Ardelyx, will participate in a Cardiorenal panel discussion at the Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 10:30 A.M. Eastern Time in Boston, MA. To acces

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Navigate the bullish trend in the market by wagering on these three enticing market sensations likely to become multi-bagger investments The post Stocks on the Launchpad: The Next 3 Market Sensations appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Dorsey Wright Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $54.30 per unit.

Ardelyx, Inc. (NASDAQ:ARDX) shares are moving Friday after the company reported its fourth-quarter financial results after the bell ...

Throughout the last three months, 7 analysts have evaluated Ardelyx (NASDAQ:ARDX), offering a diverse set of opinions from bullish to ...

Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript February 22, 2024 Ardelyx, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.09. Ardelyx, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Ardelyx Fourth […]

Shares of AXT, Inc. (NASDAQ: AXTI) rose sharply in today’s pre-market trading after the company reported better-than-expected ...

Gainers Enveric Biosciences (NASDAQ:ENVB) shares increased by 83.5% to $1.56 during Friday's pre-market session. The company's market ...

U.S. stock futures were lower this morning, with the Dow futures trading lower by around 25 points on Friday. Shares of Ardelyx, ...

Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Ardelyx (ARDX) delivered earnings and revenue surprises of -33.33% and 0.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx, Inc. (NASDAQ:ARDX) reported its fourth-quarter financial results after the bell Thursday. Here's a look at the details. The ...

IBSRELA and XPHOZAH Drive Revenue Surge as Ardelyx Strengthens Market Position

Gainers Telesis Bio (NASDAQ:TBIO) shares rose 114.3% to $0.97 during Thursday's after-market session. The market value of their ...

Ardelyx (NASDAQ:ARDX) reported its Q4 earnings results on Thursday, February 22, 2024 at 04:01 PM. Here's what investors need to know ...

Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch off to a strong start, ending FY 2023 with $2.5 million in net product sales revenue Company ends FY 2023 with $184.3 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX),

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pounce on the electric surge of analyst upgrades, guiding you through market uncertainties with considerable aplomb. The post Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities. The post 3 Revolutionary Biotech Stocks Poised for 10X Surge appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The average of price targets set by Wall Street analysts indicates a potential upside of 34.8% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Ardelyx (ARDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These are a few companies that are within the Russell 2000 Index that offer investors great returns and a bright future. The post 3 Unstoppable Russell 2000 to Buy in February appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

Ardelyx's (NYSE:ARDX) short percent of float has fallen 12.04% since its last report. The company recently reported that it has 29.02 ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These audacious innovators, all trading under $15, may erupt like financial volcanoes by 2029. The post 3 Sleeper Stocks Under $15 Ready to Explode by 2029 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. The post 3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns The post The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These are several biotech companies for investors seeking unique opportunities for great returns within the industry. The post 3 Groundbreaking Biotech Stocks to Invest in Now appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips For investors, small-cap stocks can be a great idea. They offer an opportunity for massive growth potential that can often outpace even a blue-chip stock. Small-cap stocks have relatively low market capitalization, ranging from several hundred million to $1 billion and more. If one of these names takes fire, it’s much easier to double market.... The post 7 Small-Cap Stocks to Buy for Big Gains in 2024 appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Dorsey Wright Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $51.16 per unit.

Wedbush has decided to maintain its Outperform rating of Ardelyx (NASDAQ:ARDX) and raise its price target from $9.00 to $13.00. Shares ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors tend to be attracted to stocks that trade at a cheap price due to the fact that they offer the possibility of great returns for not a large amount of capital invested. Small-cap companies typically trade at a lower price compared to larger companies. Investors should be aware that stocks that trade at a.... The post The 3 Best Under-$10 Stocks to Buy in January 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Ardelyx, Inc. (NASDAQ:ARDX) shares are trading higher Tuesday after Raymond James raised its price target on the stock, and the company ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...

In the last three months, 4 analysts have published ratings on Ardelyx (NASDAQ:ARDX), offering a diverse range of perspectives from ...

On Monday, U.S. indices ended the trading day in the green with the Nasdaq gaining 2.2% to 14,843.77. The S&P 500 rose 1.14% to ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Robinhood Markets Inc (HOOD), where a total volume of 110,128 contracts has been traded thus far today, a contract volume which is representative of approximately 11.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 64.8% of HOOD's average daily trading volume over the past month, of 17.0 million shares..

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 ...

Ardelyx, Inc. (NASDAQ: ARDX) shares are trading higher Monday after the company provided a strategic business update. Here's a look ...

Investors in Ardelyx Inc (ARDX) saw new options become available today, for the February 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain for the new February 2024 contracts and identified one put and one call contract of particular interest.

Investors in Ardelyx Inc (ARDX) saw new options begin trading today, for the February 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain for the new February 2024 contracts and identified one put and one call contract of particular interest.

Aldeyra Therapeutics Inc(NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP ...

Raymond Jamesinitiated coverage ofArdelyx Inc(NASDAQ: ARDX), noting the company's two early-stage launches ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These are a few companies that have seen considerable gains this year that still have a large percentage of short interest. The post 3 Short-Squeeze Stocks Ready for a Year-End Rally appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: Bullish Somewhat ...

Investors in Ardelyx Inc (ARDX) saw new options begin trading today, for the January 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain for the new January 2024 contracts and identified one put and one call contract of particular interest.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unlock robust upside potential by wagering on these top penny stocks to buy in a volatile market at this time. The post 7 Penny Stocks You’ll Regret Not Buying Soon: November 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $66.54 per unit.

Despite the risk, investing in over-the-counter (OTC) stocks remains popular for one reason: the potential for a massive return on ...

Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know.